Juanmonino/E+ via Getty Images
Inflarex (Nasdaq:IFRX) has received regulatory approval from the European Union for its treatment Gohibic to treat COVID-19 patients suffering from acute respiratory distress.
The European Commission has granted marketing authorization under exceptional circumstances for Gohibic, also known as vilobelimab, for the treatment of adult patients.
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217660650/image_1217660650.jpg?io=getty-c-w750
Source link